Trade Senseonics Holdings, Inc. - SENS CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.0954
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 10.307
• Open: 10.1471
• 1-Year Change: 2071.9%
• Day's Range: 9.9275 - 10.3669

Trade Senseonics Holdings, Inc. - SENS

Senseonics Holdings is a medical technology company that develops and manufactures continuous glucose monitoring (CGM) systems, specialising in long-term, implantable CGM systems for diabetes patients. It was founded in 1996 and trades on the New York Stock Exchange (NYSE) under the ticker SENS.

Headquartered in Maryland, US, the company had its initial public offering (IPO) in 2016, with an underwritten public offering of 15,800,000 shares of its common stock at $2.85 a share. Leerink Partners LLC and Canaccord Genuity acted as joint book-running managers for the offering, with Raymond James & Associates as lead manager and BTIG LLC as co-manager.

In February 2022, Senseonics’ Eversense E3 Continuous Glucose Monitoring System, touted as the first and only such CGM system, was approved for use for up to six months by the US Food and Drug Administration (FDA). The technology was reported to be available to patients in the US by the second quarter of 2022 through Senseonics’ global commercial partner, Ascensia Diabetes Care

The company’s partnership with Ascencia began in August 2020, when the pair announced a collaboration and commercialisation agreement that made Ascencia the sole distributor of Senseonics’ Eversense CGM systems worldwide. At that same time, Seseonics announced a financing agreement with Ascencia’s parent company, Masters Special Situations. The two agreements collectively made for $80m of debt and equity capital.